Patrick Soon-Shiong announces new biologic for lymphopenia
@DrPatSoonShiong: Soon-Shiong's lymphopenia breakthrough
Patrick Soon-Shiong has introduced a groundbreaking biologic treatment for lymphopenia, a condition characterized by low levels of NK and T cells.
In his recent tweet, Soon-Shiong highlighted the uniqueness of this development, noting the existence of biologics for other conditions such as anemia and neutropenia, but emphasizing that none have historically targeted lymphopenia. The new treatment is expected to offer critical support to physicians and patients, particularly those dealing with conditions like cancer, which can significantly impact immune cell counts.
The clinical trial identifier, NCT#, has been provided to facilitate access for those in need. Soon-Shiong's initiative, termed 'Cancer Bioshield', aims to fill a longstanding gap in the medical community by bolstering immune defenses against cancer-associated cell depletion.
Loading...
Soon-Shiong’s latest advance in biologic therapies further builds upon his ongoing efforts to address complex medical challenges, reflecting a broader commitment seen when he outlined a potential cancer paradigm shift at the Riyadh forum. This dedication to pioneering treatments also aligns with his recent announcement regarding a Long Covid clinical trial in California, underscoring a consistent focus on translating scientific innovation into tangible outcomes for patients across diverse diseases.
